Frazier Life Sciences Management, L.P.: 13F holdings
CIK 18921342026Q2
| Positions | 41 |
|---|
| Reported value | $4.6bn |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 41 (+3 vs prior quarter) |
|---|
| Reported value | $4.6bn (+18.2%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| MIRM MIRUM PHARMACEUTICALS INC | 7,679,684 | $899.1m | 19.6% |
| NEWAMSTERDAM PHARMA COMPANY | 18,088,902 | $613.0m | 13.3% |
| ERAS ERASCA INC | 24,975,188 | $457.5m | 10.0% |
| MBX MBX BIOSCIENCES INC | 6,652,013 | $367.2m | 8.0% |
| ARQT ARCUTIS BIOTHERAPEUTICS INC | 9,874,511 | $258.9m | 5.6% |
| TRVI TREVI THERAPEUTICS INC | 9,939,447 | $185.4m | 4.0% |
| KRYS KRYSTAL BIOTECH INC | 481,307 | $178.9m | 3.9% |
| MAZE MAZE THERAPEUTICS INC | 5,032,915 | $150.2m | 3.3% |
| PHAT PHATHOM PHARMACEUTICALS INC | 12,466,489 | $135.3m | 2.9% |
| PVLA PALVELLA THERAPEUTICS INC NE | 882,400 | $134.8m | 2.9% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1892134")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples